CD226 (Cluster of Differentiation 226), also known as DNAM1 or TLiSA1, is a pivotal member of the immunoglobulin superfamily. CD226 is found to be expressed in a variety of cells, including natural killer cells, platelets, T cells, monocytes, B cells, mature mast cells, and dendritic cells. Although CD226 is present in a diverse range of cells, it is not present in progenitors of the erythroid lineage.
Its Gene ID: 10666, UniProtKB ID: Q15762, and OMIM ID: 605397.
As an adhesion molecule, CD226 plays an indispensable role in promoting the activation, migration, proliferation, and differentiation of CD8+ T cells. CD226 also contributes to activating and enhancing the cytotoxicity of natural killer cells. In addition, CD226 is capable of stimulating the release of cytokines, thereby promoting anti-tumor immune responses. In summary, the combination of CD226 and its ligand not only regulates a variety of cellular functions but also participates in the immune recognition process.
Fig.1 Role of CD226 in anti-TIGIT immunotherapy.1
Increasing evidence shows that CD226 is closely linked to the development of a variety of diseases, including tumorigenesis, autoimmune diseases, and infectious diseases. Scientists found that the downregulation of CD226 expression on liver cancer cells is closely related to the survival time and survival rate of patients. In addition, CD226 gene polymorphisms are directly related to tumor risk. Taken together, modulating the expression and functions of CD226 may become promising strategies for the treatment of immune-related diseases and tumors.
After binding to the ligand, CD226 is phosphorylated by protein kinase C. Specific adhesion molecules subsequently cross-link CD226, leading to its recruitment to lipid rafts and promoting its association with the actin cytoskeleton. Another pathway is the co-phosphorylation of SLP-76 by CD226 and CD244, a signaling cascade that ultimately leads to Ca2+ influx and cytoskeletal reorganization.
At Creative Biolabs, we offer dozens of different anti-CD226 antibody products. Our CD226 antibodies are recombinantly expressed and validated for high affinity and specificity. You can always choose the product that suits your research purpose from our antibody portfolio, please contact us for more information about CD226 antibodies.
Anti-CD226 (ECD domain) Neutralizing Antibody (V3S-0822-YC680) (CAT#: V3S-0822-YC680)
Target: CD226
Host Species: Mouse
Target Species: Human,
Application: Neut,WB,